PureFlo Pharmaceutical Compounding
Saint-Gobain's PureFlo Capsules for Pharmaceutical Compounding are economic, efficient, and easy-to-use. The filter capsules are available in five different size formats and with two different membrane options, polyethersulfone (PES) and polytetrafluoroethylene (PTFE) to cover a multitude of small to large batch formulations.
- 100% Integrity tested
- Shipped with a Certificate of Conformance
- Multiple pore sizes to choose from for the removal of particles and microorganisms
- Wide range of filter sizes available to ensure complete filtration of targeted batch volume
- Built-in prefilter options available to improve capacity for difficult-to-filter solutions
- Customizable, easy-to-use connections
- Sterile and non-sterile options available
At Liquidyne, we prioritize our commitment to quality and consistency. In 2017 we achieved ISO 9001:2015 Quality Management System certification to ensure we can repeatedly deliver consistently high-quality products and solutions. Being an ISO 9001 facility, together with our USP Class VI Testing, ASME Bioprocessing Equipment (BPE), and EHEDG certification guarantee, we have the methodologies to assure quality. We will quickly and accurately rectify any issues if any of our products are ever in non-conformance.
"Thanks so much! What a quick turn around. It is a pleasure working with Liquidyne."
Process Development Manager
"I received the cart yesterday, thanks for the fast delivery! It feels sturdy. I sat on it. It does not bounce. It is also easy to clean and wipe or wash down."
Vice President, Analytical Development and Manufacturing
"Thanks again for reacting so quickly and meeting me halfway with the element. We will be able to get installed and have things keep moving overnight with the night crew. The little things like this are always greatly appreciated when working with Liquidyne."
“This pump cut our processing time from 3 days to 1 shift. I’m not giving this pump back. You will have to come and get it if you want it... and that won’t likely happen.”
VP Antibody Manufacturing